APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neuroendocrine Carcinoma Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Neuroendocrine Carcinoma Drugs Industry Growth and Trends Forecast to 2032

20 December 202597 pages

Choose your research edition.

Industry ResearchNeuroendocrine Carcinoma Drugs Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Neuroendocrine Carcinoma Drugs Industry Growth and Trends Forecast to 203297 pages · $3,450 USDMarket StructureGlobal Neuroendocrine Carcinoma Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neuroendocrine Carcinoma Drugs Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Neuroendocrine Carcinoma Drugs Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Neuroendocrine Carcinoma Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Neuroendocrine Carcinoma Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Neuroendocrine Carcinoma Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neuroendocrine Carcinoma Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Neuroendocrine Carcinoma Drugs include Novartis AG, Roche, Xiaflex, Molecular Insight pharmaceuticals and Callisto Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Neuroendocrine Carcinoma Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Neuroendocrine Carcinoma Drugs market size, estimates, and forecasts are presented in terms of sales volume (k tons) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Neuroendocrine Carcinoma Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Neuroendocrine Carcinoma Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Neuroendocrine Carcinoma Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Neuroendocrine Carcinoma Drugs Market by Company

Novartis AG

Roche

Xiaflex

Molecular Insight pharmaceuticals

Callisto Pharmaceuticals

Neuroendocrine Carcinoma Drugs Segment by Type

Targeted Therapy

Somatostatin Analogs

Chemotherapy

Neuroendocrine Carcinoma Drugs Segment by Application

Oncology Centres

Clinics

Hospital

Ambulatory Surgery Centres

Neuroendocrine Carcinoma Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuroendocrine Carcinoma Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neuroendocrine Carcinoma Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuroendocrine Carcinoma Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Neuroendocrine Carcinoma Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Neuroendocrine Carcinoma Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Targeted Therapy Table 2. Major Company of Somatostatin Analogs Table 3. Major Company of Chemotherapy Table 4. Global Neuroendocrine Carcinoma Drugs Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Neuroendocrine Carcinoma Drugs Sales by Type (2021-2026) & (k tons) Table 6. Global Neuroendocrine Carcinoma Drugs Sales Market Share in Volume by Type (2021-2026) Table 7. Global Neuroendocrine Carcinoma Drugs Sales by Type (2021-2026) & (US$ Million) Table 8. Global Neuroendocrine Carcinoma Drugs Sales Market Share in Value by Type (2021-2026) Table 9. Global Neuroendocrine Carcinoma Drugs Price by Type (2021-2026) & (US$/ton) Table 10. Global Neuroendocrine Carcinoma Drugs Sales by Type (2027-2032) & (k tons) Table 11. Global Neuroendocrine Carcinoma Drugs Sales Market Share in Volume by Type (2027-2032) Table 12. Global Neuroendocrine Carcinoma Drugs Sales by Type (2027-2032) & (US$ Million) Table 13. Global Neuroendocrine Carcinoma Drugs Sales Market Share in Value by Type (2027-2032) Table 14. Global Neuroendocrine Carcinoma Drugs Price by Type (2027-2032) & (US$/ton) Table 15. North America Neuroendocrine Carcinoma Drugs Sales by Type (2021-2026) & (k tons) Table 16. North America Neuroendocrine Carcinoma Drugs Sales by Type (2021-2026) & (US$ Million) Table 17. Europe Neuroendocrine Carcinoma Drugs Sales by Type (2021-2026) & (k tons) Table 18. Europe Neuroendocrine Carcinoma Drugs Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific Neuroendocrine Carcinoma Drugs Sales by Type (2021-2026) & (k tons) Table 20. Asia-Pacific Neuroendocrine Carcinoma Drugs Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America Neuroendocrine Carcinoma Drugs Sales by Type (2021-2026) & (k tons) Table 22. Latin America Neuroendocrine Carcinoma Drugs Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa Neuroendocrine Carcinoma Drugs Sales by Type (2021-2026) & (k tons) Table 24. Middle East and Africa Neuroendocrine Carcinoma Drugs Sales by Type (2021-2026) & (US$ Million) Table 25. Neuroendocrine Carcinoma Drugs Industry Trends Table 26. Neuroendocrine Carcinoma Drugs Industry Drivers Table 27. Neuroendocrine Carcinoma Drugs Industry Opportunities and Challenges Table 28. Neuroendocrine Carcinoma Drugs Industry Restraints Table 29. Global Neuroendocrine Carcinoma Drugs Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global Neuroendocrine Carcinoma Drugs Revenue Market Share by Company (2021-2026) Table 31. Global Neuroendocrine Carcinoma Drugs Sales by Company (2021-2026) & (k tons) Table 32. Global Neuroendocrine Carcinoma Drugs Sales Share by Company (2021-2026) Table 33. Global Neuroendocrine Carcinoma Drugs Market Price by Company (2021-2026) & (US$/ton) Table 34. Global Neuroendocrine Carcinoma Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global Neuroendocrine Carcinoma Drugs Major Company Production Sites and Headquarters Table 36. Global Neuroendocrine Carcinoma Drugs Company, Product Type & Application Table 37. Global Neuroendocrine Carcinoma Drugs Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global Neuroendocrine Carcinoma Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global Neuroendocrine Carcinoma Drugs Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global Neuroendocrine Carcinoma Drugs Sales by Region (2021-2026) & (k tons) Table 42. Global Neuroendocrine Carcinoma Drugs Sales Market Share in Volume by Region (2021-2026) Table 43. Global Neuroendocrine Carcinoma Drugs Sales by Region (2021-2026) & (US$ Million) Table 44. Global Neuroendocrine Carcinoma Drugs Sales Market Share in Value by Region (2021-2026) Table 45. Global Neuroendocrine Carcinoma Drugs Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 46. Global Neuroendocrine Carcinoma Drugs Sales by Region (2027-2032) & (k tons) Table 47. Global Neuroendocrine Carcinoma Drugs Sales Market Share in Volume by Region (2027-2032) Table 48. Global Neuroendocrine Carcinoma Drugs Sales by Region (2027-2032) & (US$ Million) Table 49. Global Neuroendocrine Carcinoma Drugs Sales Market Share in Value by Region (2027-2032) Table 50. Global Neuroendocrine Carcinoma Drugs Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2027-2032) Table 51. Global Neuroendocrine Carcinoma Drugs Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global Neuroendocrine Carcinoma Drugs Sales by Application (2021-2026) & (k tons) Table 53. Global Neuroendocrine Carcinoma Drugs Sales Market Share in Volume by Application (2021-2026) Table 54. Global Neuroendocrine Carcinoma Drugs Sales by Application (2021-2026) & (US$ Million) Table 55. Global Neuroendocrine Carcinoma Drugs Sales Market Share in Value by Application (2021-2026) Table 56. Global Neuroendocrine Carcinoma Drugs Price by Application (2021-2026) & (US$/ton) Table 57. Global Neuroendocrine Carcinoma Drugs Sales by Application (2027-2032) & (k tons) Table 58. Global Neuroendocrine Carcinoma Drugs Sales Market Share in Volume by Application (2027-2032) Table 59. Global Neuroendocrine Carcinoma Drugs Sales by Application (2027-2032) & (US$ Million) Table 60. Global Neuroendocrine Carcinoma Drugs Sales Market Share in Value by Application (2027-2032) Table 61. Global Neuroendocrine Carcinoma Drugs Price by Application (2027-2032) & (US$/ton) Table 62. North America Neuroendocrine Carcinoma Drugs Sales by Application (2021-2026) & (k tons) Table 63. North America Neuroendocrine Carcinoma Drugs Sales by Application (2021-2026) & (US$ Million) Table 64. Europe Neuroendocrine Carcinoma Drugs Sales by Application (2021-2026) & (k tons) Table 65. Europe Neuroendocrine Carcinoma Drugs Sales by Application (2021-2026) & (US$ Million) Table 66. Asia-Pacific Neuroendocrine Carcinoma Drugs Sales by Application (2021-2026) & (k tons) Table 67. Asia-Pacific Neuroendocrine Carcinoma Drugs Sales by Application (2021-2026) & (US$ Million) Table 68. Latin America Neuroendocrine Carcinoma Drugs Sales by Application (2021-2026) & (k tons) Table 69. Latin America Neuroendocrine Carcinoma Drugs Sales by Application (2021-2026) & (US$ Million) Table 70. Middle East and Africa Neuroendocrine Carcinoma Drugs Sales by Application (2021-2026) & (k tons) Table 71. Middle East and Africa Neuroendocrine Carcinoma Drugs Sales by Application (2021-2026) & (US$ Million) Table 72. Novartis AG Company Information Table 73. Novartis AG Business Overview Table 74. Novartis AG Neuroendocrine Carcinoma Drugs Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 75. Novartis AG Neuroendocrine Carcinoma Drugs Product Portfolio Table 76. Novartis AG Recent Development Table 77. Roche Company Information Table 78. Roche Business Overview Table 79. Roche Neuroendocrine Carcinoma Drugs Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 80. Roche Neuroendocrine Carcinoma Drugs Product Portfolio Table 81. Roche Recent Development Table 82. Xiaflex Company Information Table 83. Xiaflex Business Overview Table 84. Xiaflex Neuroendocrine Carcinoma Drugs Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 85. Xiaflex Neuroendocrine Carcinoma Drugs Product Portfolio Table 86. Xiaflex Recent Development Table 87. Molecular Insight pharmaceuticals Company Information Table 88. Molecular Insight pharmaceuticals Business Overview Table 89. Molecular Insight pharmaceuticals Neuroendocrine Carcinoma Drugs Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 90. Molecular Insight pharmaceuticals Neuroendocrine Carcinoma Drugs Product Portfolio Table 91. Molecular Insight pharmaceuticals Recent Development Table 92. Callisto Pharmaceuticals Company Information Table 93. Callisto Pharmaceuticals Business Overview Table 94. Callisto Pharmaceuticals Neuroendocrine Carcinoma Drugs Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 95. Callisto Pharmaceuticals Neuroendocrine Carcinoma Drugs Product Portfolio Table 96. Callisto Pharmaceuticals Recent Development Table 97. North America Neuroendocrine Carcinoma Drugs Market Size Growth Rate (CAGR) by Country (k tons): 2021 VS 2025 VS 2032 Table 98. North America Neuroendocrine Carcinoma Drugs Sales by Country (2021-2026) & (k tons) Table 99. North America Neuroendocrine Carcinoma Drugs Sales Market Share by Country (2021-2026) Table 100. North America Neuroendocrine Carcinoma Drugs Sales Forecast by Country (2027-2032) & (k tons) Table 101. North America Neuroendocrine Carcinoma Drugs Sales Market Share Forecast by Country (2027-2032) Table 102. North America Neuroendocrine Carcinoma Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 103. North America Neuroendocrine Carcinoma Drugs Market Size by Country (2021-2026) & (US$ Million) Table 104. North America Neuroendocrine Carcinoma Drugs Market Share by Country (2021-2026) Table 105. North America Neuroendocrine Carcinoma Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 106. North America Neuroendocrine Carcinoma Drugs Market Share Forecast by Country (2027-2032) Table 107. Europe Neuroendocrine Carcinoma Drugs Market Size Growth Rate (CAGR) by Country (k tons): 2021 VS 2025 VS 2032 Table 108. Europe Neuroendocrine Carcinoma Drugs Sales by Country (2021-2026) & (k tons) Table 109. Europe Neuroendocrine Carcinoma Drugs Sales Market Share by Country (2021-2026) Table 110. Europe Neuroendocrine Carcinoma Drugs Sales Forecast by Country (2027-2032) & (k tons) Table 111. Europe Neuroendocrine Carcinoma Drugs Sales Market Share Forecast by Country (2027-2032) Table 112. Europe Neuroendocrine Carcinoma Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 113. Europe Neuroendocrine Carcinoma Drugs Market Size by Country (2021-2026) & (US$ Million) Table 114. Europe Neuroendocrine Carcinoma Drugs Market Share by Country (2021-2026) Table 115. Europe Neuroendocrine Carcinoma Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 116. Europe Neuroendocrine Carcinoma Drugs Market Share Forecast by Country (2027-2032) Table 117. Asia-Pacific Neuroendocrine Carcinoma Drugs Market Size Growth Rate (CAGR) by Country (k tons): 2021 VS 2025 VS 2032 Table 118. Asia-Pacific Neuroendocrine Carcinoma Drugs Sales by Country (2021-2026) & (k tons) Table 119. Asia-Pacific Neuroendocrine Carcinoma Drugs Sales Market Share by Country (2021-2026) Table 120. Asia-Pacific Neuroendocrine Carcinoma Drugs Sales Forecast by Country (2027-2032) & (k tons) Table 121. Asia-Pacific Neuroendocrine Carcinoma Drugs Sales Market Share Forecast by Country (2027-2032) Table 122. Asia-Pacific Neuroendocrine Carcinoma Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 123. Asia-Pacific Neuroendocrine Carcinoma Drugs Market Size by Country (2021-2026) & (US$ Million) Table 124. Asia-Pacific Neuroendocrine Carcinoma Drugs Market Share by Country (2021-2026) Table 125. Asia-Pacific Neuroendocrine Carcinoma Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 126. Asia-Pacific Neuroendocrine Carcinoma Drugs Market Share Forecast by Country (2027-2032) Table 127. Latin America Neuroendocrine Carcinoma Drugs Market Size Growth Rate (CAGR) by Country (k tons): 2021 VS 2025 VS 2032 Table 128. Latin America Neuroendocrine Carcinoma Drugs Sales by Country (2021-2026) & (k tons) Table 129. Latin America Neuroendocrine Carcinoma Drugs Sales Market Share by Country (2021-2026) Table 130. Latin America Neuroendocrine Carcinoma Drugs Sales Forecast by Country (2027-2032) & (k tons) Table 131. Latin America Neuroendocrine Carcinoma Drugs Sales Market Share Forecast by Country (2027-2032) Table 132. Latin America Neuroendocrine Carcinoma Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 133. Latin America Neuroendocrine Carcinoma Drugs Market Size by Country (2021-2026) & (US$ Million) Table 134. Latin America Neuroendocrine Carcinoma Drugs Market Share by Country (2021-2026) Table 135. Latin America Neuroendocrine Carcinoma Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 136. Latin America Neuroendocrine Carcinoma Drugs Market Share Forecast by Country (2027-2032) Table 137. Middle East and Africa Neuroendocrine Carcinoma Drugs Market Size Growth Rate (CAGR) by Country (k tons): 2021 VS 2025 VS 2032 Table 138. Middle East and Africa Neuroendocrine Carcinoma Drugs Sales by Country (2021-2026) & (k tons) Table 139. Middle East and Africa Neuroendocrine Carcinoma Drugs Sales Market Share by Country (2021-2026) Table 140. Middle East and Africa Neuroendocrine Carcinoma Drugs Sales Forecast by Country (2027-2032) & (k tons) Table 141. Middle East and Africa Neuroendocrine Carcinoma Drugs Sales Market Share Forecast by Country (2027-2032) Table 142. Middle East and Africa Neuroendocrine Carcinoma Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 143. Middle East and Africa Neuroendocrine Carcinoma Drugs Market Size by Country (2021-2026) & (US$ Million) Table 144. Middle East and Africa Neuroendocrine Carcinoma Drugs Market Share by Country (2021-2026) Table 145. Middle East and Africa Neuroendocrine Carcinoma Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 146. Middle East and Africa Neuroendocrine Carcinoma Drugs Market Share Forecast by Country (2027-2032) Table 147. Key Raw Materials Table 148. Raw Materials Key Suppliers Table 149. Neuroendocrine Carcinoma Drugs Distributors List Table 150. Neuroendocrine Carcinoma Drugs Customers List Table 151. Research Programs/Design for This Report Table 152. Authors List of This Report Table 153. Secondary Sources Table 154. Primary Sources List of Figures Figure 1. Neuroendocrine Carcinoma Drugs Image Figure 2. Global Neuroendocrine Carcinoma Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neuroendocrine Carcinoma Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Neuroendocrine Carcinoma Drugs Sales (2021-2032) & (k tons) Figure 5. Targeted Therapy Image Figure 6. Global Targeted Therapy Sales YoY Growth (2021-2032) & (k tons) Figure 7. Somatostatin Analogs Image Figure 8. Global Somatostatin Analogs Sales YoY Growth (2021-2032) & (k tons) Figure 9. Chemotherapy Image Figure 10. Global Chemotherapy Sales YoY Growth (2021-2032) & (k tons) Figure 11. Global Neuroendocrine Carcinoma Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global Neuroendocrine Carcinoma Drugs Market Share by Type 2025 VS 2032 Figure 13. North America Neuroendocrine Carcinoma Drugs Sales Market Share in Volume by Type in 2025 Figure 14. North America Neuroendocrine Carcinoma Drugs Sales Market Share in Value by Type in 2025 Figure 15. Europe Neuroendocrine Carcinoma Drugs Sales Market Share in Volume by Type in 2025 Figure 16. Europe Neuroendocrine Carcinoma Drugs Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific Neuroendocrine Carcinoma Drugs Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific Neuroendocrine Carcinoma Drugs Sales Market Share in Value by Type in 2025 Figure 19. Latin America Neuroendocrine Carcinoma Drugs Sales Market Share in Volume by Type in 2025 Figure 20. Latin America Neuroendocrine Carcinoma Drugs Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa Neuroendocrine Carcinoma Drugs Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa Neuroendocrine Carcinoma Drugs Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 Neuroendocrine Carcinoma Drugs Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Oncology Centres Image Figure 26. Global Oncology Centres Sales YoY Growth (2021-2032) & (k tons) Figure 27. Clinics Image Figure 28. Global Clinics Sales YoY Growth (2021-2032) & (k tons) Figure 29. Hospital Image Figure 30. Global Hospital Sales YoY Growth (2021-2032) & (k tons) Figure 31. Ambulatory Surgery Centres Image Figure 32. Global Ambulatory Surgery Centres Sales YoY Growth (2021-2032) & (k tons) Figure 33. Global Neuroendocrine Carcinoma Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Neuroendocrine Carcinoma Drugs Market Share by Application 2025 VS 2032 Figure 35. North America Neuroendocrine Carcinoma Drugs Sales Market Share in Volume by Application in 2025 Figure 36. North America Neuroendocrine Carcinoma Drugs Sales Market Share in Value by Application in 2025 Figure 37. Europe Neuroendocrine Carcinoma Drugs Sales Market Share in Volume by Application in 2025 Figure 38. Europe Neuroendocrine Carcinoma Drugs Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific Neuroendocrine Carcinoma Drugs Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific Neuroendocrine Carcinoma Drugs Sales Market Share in Value by Application in 2025 Figure 41. Latin America Neuroendocrine Carcinoma Drugs Sales Market Share in Volume by Application in 2025 Figure 42. Latin America Neuroendocrine Carcinoma Drugs Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa Neuroendocrine Carcinoma Drugs Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa Neuroendocrine Carcinoma Drugs Sales Market Share in Value by Application in 2025 Figure 45. North America Neuroendocrine Carcinoma Drugs Sales by Country: 2021 VS 2025 VS 2032 (k tons) Figure 46. North America Neuroendocrine Carcinoma Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America Neuroendocrine Carcinoma Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America Neuroendocrine Carcinoma Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Neuroendocrine Carcinoma Drugs Sales by Country: 2021 VS 2025 VS 2032 (k tons) Figure 50. Europe Neuroendocrine Carcinoma Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Neuroendocrine Carcinoma Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe Neuroendocrine Carcinoma Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Neuroendocrine Carcinoma Drugs Sales by Country: 2021 VS 2025 VS 2032 (k tons) Figure 54. Asia-Pacific Neuroendocrine Carcinoma Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Neuroendocrine Carcinoma Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific Neuroendocrine Carcinoma Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Neuroendocrine Carcinoma Drugs Sales by Country: 2021 VS 2025 VS 2032 (k tons) Figure 58. Latin America Neuroendocrine Carcinoma Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Neuroendocrine Carcinoma Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America Neuroendocrine Carcinoma Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Neuroendocrine Carcinoma Drugs Sales by Country: 2021 VS 2025 VS 2032 (k tons) Figure 62. Middle East and Africa Neuroendocrine Carcinoma Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Neuroendocrine Carcinoma Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa Neuroendocrine Carcinoma Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Neuroendocrine Carcinoma Drugs Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. Neuroendocrine Carcinoma Drugs Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Targeted Therapy
  • Somatostatin Analogs
  • Chemotherapy
Applications
  • Oncology Centres
  • Clinics
  • Hospital
  • Ambulatory Surgery Centres
Companies covered
  • Novartis AG
  • Roche
  • Xiaflex
  • Molecular Insight pharmaceuticals
  • Callisto Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Neuroendocrine Carcinoma Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Neuroendocrine Carcinoma Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Neuroendocrine Carcinoma Drugs Market by Type
  6. 1.3.1 Targeted Therapy
  7. 1.3.2 Somatostatin Analogs
  8. 1.3.3 Chemotherapy
  9. 1.4 Global Neuroendocrine Carcinoma Drugs Market Size by Type
  10. 1.4.1 Global Neuroendocrine Carcinoma Drugs Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global Neuroendocrine Carcinoma Drugs Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global Neuroendocrine Carcinoma Drugs Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America Neuroendocrine Carcinoma Drugs Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe Neuroendocrine Carcinoma Drugs Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific Neuroendocrine Carcinoma Drugs Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America Neuroendocrine Carcinoma Drugs Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa Neuroendocrine Carcinoma Drugs Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Neuroendocrine Carcinoma Drugs Industry Trends
  2. 2.2 Neuroendocrine Carcinoma Drugs Industry Drivers
  3. 2.3 Neuroendocrine Carcinoma Drugs Industry Opportunities and Challenges
  4. 2.4 Neuroendocrine Carcinoma Drugs Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Neuroendocrine Carcinoma Drugs Revenue (2021-2026)
  2. 3.2 Global Top Players by Neuroendocrine Carcinoma Drugs Sales (2021-2026)
  3. 3.3 Global Top Players by Neuroendocrine Carcinoma Drugs Price (2021-2026)
  4. 3.4 Global Neuroendocrine Carcinoma Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Neuroendocrine Carcinoma Drugs Major Company Production Sites & Headquarters
  6. 3.6 Global Neuroendocrine Carcinoma Drugs Company, Product Type & Application
  7. 3.7 Global Neuroendocrine Carcinoma Drugs Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Neuroendocrine Carcinoma Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Neuroendocrine Carcinoma Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Neuroendocrine Carcinoma Drugs Tier 1, Tier 2, and Tier 3
4 Neuroendocrine Carcinoma Drugs Regional Status and Outlook
  1. 4.1 Global Neuroendocrine Carcinoma Drugs Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Neuroendocrine Carcinoma Drugs Historic Market Size by Region
  3. 4.2.1 Global Neuroendocrine Carcinoma Drugs Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Neuroendocrine Carcinoma Drugs Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Neuroendocrine Carcinoma Drugs Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Neuroendocrine Carcinoma Drugs Forecasted Market Size by Region
  7. 4.3.1 Global Neuroendocrine Carcinoma Drugs Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Neuroendocrine Carcinoma Drugs Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Neuroendocrine Carcinoma Drugs Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Neuroendocrine Carcinoma Drugs by Application
  1. 5.1 Neuroendocrine Carcinoma Drugs Market by Application
  2. 5.1.1 Oncology Centres
  3. 5.1.2 Clinics
  4. 5.1.3 Hospital
  5. 5.1.4 Ambulatory Surgery Centres
  6. 5.2 Global Neuroendocrine Carcinoma Drugs Market Size by Application
  7. 5.2.1 Global Neuroendocrine Carcinoma Drugs Market Size Overview by Application (2021-2032)
  8. 5.2.2 Global Neuroendocrine Carcinoma Drugs Historic Market Size Review by Application (2021-2026)
  9. 5.2.3 Global Neuroendocrine Carcinoma Drugs Forecasted Market Size by Application (2027-2032)
  10. 5.3 Key Regions Market Size by Application
  11. 5.3.1 North America Neuroendocrine Carcinoma Drugs Sales Breakdown by Application (2021-2026)
  12. 5.3.2 Europe Neuroendocrine Carcinoma Drugs Sales Breakdown by Application (2021-2026)
  13. 5.3.3 Asia-Pacific Neuroendocrine Carcinoma Drugs Sales Breakdown by Application (2021-2026)
  14. 5.3.4 South America Neuroendocrine Carcinoma Drugs Sales Breakdown by Application (2021-2026)
  15. 5.3.5 Middle East and Africa Neuroendocrine Carcinoma Drugs Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Novartis AG
  2. 6.1.1 Novartis AG Company Information
  3. 6.1.2 Novartis AG Business Overview
  4. 6.1.3 Novartis AG Neuroendocrine Carcinoma Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Novartis AG Neuroendocrine Carcinoma Drugs Product Portfolio
  6. 6.1.5 Novartis AG Recent Developments
  7. 6.2 Roche
  8. 6.2.1 Roche Company Information
  9. 6.2.2 Roche Business Overview
  10. 6.2.3 Roche Neuroendocrine Carcinoma Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Roche Neuroendocrine Carcinoma Drugs Product Portfolio
  12. 6.2.5 Roche Recent Developments
  13. 6.3 Xiaflex
  14. 6.3.1 Xiaflex Company Information
  15. 6.3.2 Xiaflex Business Overview
  16. 6.3.3 Xiaflex Neuroendocrine Carcinoma Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Xiaflex Neuroendocrine Carcinoma Drugs Product Portfolio
  18. 6.3.5 Xiaflex Recent Developments
  19. 6.4 Molecular Insight pharmaceuticals
  20. 6.4.1 Molecular Insight pharmaceuticals Company Information
  21. 6.4.2 Molecular Insight pharmaceuticals Business Overview
  22. 6.4.3 Molecular Insight pharmaceuticals Neuroendocrine Carcinoma Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Molecular Insight pharmaceuticals Neuroendocrine Carcinoma Drugs Product Portfolio
  24. 6.4.5 Molecular Insight pharmaceuticals Recent Developments
  25. 6.5 Callisto Pharmaceuticals
  26. 6.5.1 Callisto Pharmaceuticals Company Information
  27. 6.5.2 Callisto Pharmaceuticals Business Overview
  28. 6.5.3 Callisto Pharmaceuticals Neuroendocrine Carcinoma Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Callisto Pharmaceuticals Neuroendocrine Carcinoma Drugs Product Portfolio
  30. 6.5.5 Callisto Pharmaceuticals Recent Developments
7 North America by Country
  1. 7.1 North America Neuroendocrine Carcinoma Drugs Sales by Country
  2. 7.1.1 North America Neuroendocrine Carcinoma Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Neuroendocrine Carcinoma Drugs Sales by Country (2021-2026)
  4. 7.1.3 North America Neuroendocrine Carcinoma Drugs Sales Forecast by Country (2027-2032)
  5. 7.2 North America Neuroendocrine Carcinoma Drugs Market Size by Country
  6. 7.2.1 North America Neuroendocrine Carcinoma Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Neuroendocrine Carcinoma Drugs Market Size by Country (2021-2026)
  8. 7.2.3 North America Neuroendocrine Carcinoma Drugs Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Neuroendocrine Carcinoma Drugs Sales by Country
  2. 8.1.1 Europe Neuroendocrine Carcinoma Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Neuroendocrine Carcinoma Drugs Sales by Country (2021-2026)
  4. 8.1.3 Europe Neuroendocrine Carcinoma Drugs Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Neuroendocrine Carcinoma Drugs Market Size by Country
  6. 8.2.1 Europe Neuroendocrine Carcinoma Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Neuroendocrine Carcinoma Drugs Market Size by Country (2021-2026)
  8. 8.2.3 Europe Neuroendocrine Carcinoma Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Neuroendocrine Carcinoma Drugs Sales by Country
  2. 9.1.1 Asia-Pacific Neuroendocrine Carcinoma Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Neuroendocrine Carcinoma Drugs Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Neuroendocrine Carcinoma Drugs Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Neuroendocrine Carcinoma Drugs Market Size by Country
  6. 9.2.1 Asia-Pacific Neuroendocrine Carcinoma Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Neuroendocrine Carcinoma Drugs Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Neuroendocrine Carcinoma Drugs Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Neuroendocrine Carcinoma Drugs Sales by Country
  2. 10.1.1 South America Neuroendocrine Carcinoma Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Neuroendocrine Carcinoma Drugs Sales by Country (2021-2026)
  4. 10.1.3 South America Neuroendocrine Carcinoma Drugs Sales Forecast by Country (2027-2032)
  5. 10.2 South America Neuroendocrine Carcinoma Drugs Market Size by Country
  6. 10.2.1 South America Neuroendocrine Carcinoma Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Neuroendocrine Carcinoma Drugs Market Size by Country (2021-2026)
  8. 10.2.3 South America Neuroendocrine Carcinoma Drugs Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Neuroendocrine Carcinoma Drugs Sales by Country
  2. 11.1.1 Middle East and Africa Neuroendocrine Carcinoma Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Neuroendocrine Carcinoma Drugs Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Neuroendocrine Carcinoma Drugs Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Neuroendocrine Carcinoma Drugs Market Size by Country
  6. 11.2.1 Middle East and Africa Neuroendocrine Carcinoma Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Neuroendocrine Carcinoma Drugs Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Neuroendocrine Carcinoma Drugs Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Neuroendocrine Carcinoma Drugs Value Chain Analysis
  2. 12.1.1 Neuroendocrine Carcinoma Drugs Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Neuroendocrine Carcinoma Drugs Production Mode & Process
  7. 12.2 Neuroendocrine Carcinoma Drugs Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Neuroendocrine Carcinoma Drugs Distributors
  10. 12.2.3 Neuroendocrine Carcinoma Drugs Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst